Jennifer L. Sherr

8.7k total citations · 3 hit papers
115 papers, 3.5k citations indexed

About

Jennifer L. Sherr is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Jennifer L. Sherr has authored 115 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Endocrinology, Diabetes and Metabolism, 83 papers in Surgery and 69 papers in Genetics. Recurrent topics in Jennifer L. Sherr's work include Diabetes Management and Research (109 papers), Pancreatic function and diabetes (82 papers) and Diabetes and associated disorders (69 papers). Jennifer L. Sherr is often cited by papers focused on Diabetes Management and Research (109 papers), Pancreatic function and diabetes (82 papers) and Diabetes and associated disorders (69 papers). Jennifer L. Sherr collaborates with scholars based in United States, United Kingdom and Germany. Jennifer L. Sherr's co-authors include William V. Tamborlane, Stuart A. Weinzimer, Eda Cengiz, Roy W. Beck, David M. Maahs, Lori Carria, Gregory P. Forlenza, Reinhard W. Holl, R. Paul Wadwa and Mark A. Clements and has published in prestigious journals such as Science, JAMA and Journal of Clinical Investigation.

In The Last Decade

Jennifer L. Sherr

106 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes

2020 268 citations Lori M. Laffel, Mark A. Clements et al. profile →
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus

2021 179 citations Jennifer L. Sherr, Bruce W. Bode et al. profile →
Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey

2024 42 citations Jennifer L. Sherr, Lori M. Laffel et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer L. Sherr United States	32	3.1k	2.2k	1.9k	161	145	115	3.5k
Laurel H. Messer United States	32	2.4k 0.8×	1.6k 0.7×	1.5k 0.8×	106 0.7×	203 1.4×	92	2.8k
Gregory P. Forlenza United States	36	3.4k 1.1×	2.6k 1.2×	2.2k 1.1×	96 0.6×	197 1.4×	141	3.9k
Eda Cengiz United States	28	2.4k 0.8×	1.6k 0.7×	1.4k 0.7×	146 0.9×	97 0.7×	79	2.8k
Nataša Bratina Slovenia	29	2.0k 0.7×	1.6k 0.7×	1.4k 0.7×	95 0.6×	110 0.8×	82	2.5k
Hood Thabit United Kingdom	31	2.7k 0.9×	1.9k 0.9×	1.6k 0.8×	205 1.3×	205 1.4×	97	3.4k
Lalantha Leelarathna United Kingdom	33	2.5k 0.8×	1.7k 0.8×	1.4k 0.7×	91 0.6×	162 1.1×	91	2.8k
Craig Kollman United States	28	2.4k 0.8×	1.7k 0.8×	1.5k 0.8×	123 0.8×	87 0.6×	52	3.3k
Stephanie N. DuBose United States	20	2.8k 0.9×	1.7k 0.8×	1.8k 0.9×	134 0.8×	142 1.0×	31	3.1k
Ohad Cohen Israel	34	2.6k 0.8×	1.5k 0.7×	1.1k 0.6×	155 1.0×	68 0.5×	161	3.5k
Trang T. Ly United States	32	2.3k 0.8×	1.7k 0.8×	1.4k 0.7×	82 0.5×	114 0.8×	98	2.5k

Countries citing papers authored by Jennifer L. Sherr

Since Specialization

Citations

This map shows the geographic impact of Jennifer L. Sherr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer L. Sherr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer L. Sherr more than expected).

Fields of papers citing papers by Jennifer L. Sherr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer L. Sherr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer L. Sherr. The network helps show where Jennifer L. Sherr may publish in the future.

Co-authorship network of co-authors of Jennifer L. Sherr

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer L. Sherr. A scholar is included among the top collaborators of Jennifer L. Sherr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer L. Sherr. Jennifer L. Sherr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferrat, Lauric, Nicholas J. Thomas, Diane K. Wherrett, et al.. (2025). Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study. Diabetes Care. 48(9). 1571–1580. 1 indexed citations

Igudesman, Daria, Laura M. Nally, Alyssa Grimshaw, et al.. (2025). Dietary Patterns for Weight and Glycemic Management in Persons With Type 1 Diabetes: A Meta-analysis of Clinical Trials. The Journal of Clinical Endocrinology & Metabolism. 110(11). 3289–3300. 2 indexed citations

Sherr, Jennifer L. & Erin Cobry. (2025). The Future of Dual Glucose–Ketone Monitoring in Youth with Diabetes. Diabetes Technology & Therapeutics. 27(S4). S36–S43.

Messer, Laurel H., Gregory P. Forlenza, Linda Gonder‐Frederick, et al.. (2025). Practical Considerations and Implementation of Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. 27(3_suppl). S72–S78. 1 indexed citations

Riddell, Michael C., Robin L. Gal, Susana R. Patton, et al.. (2024). Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics. 26(10). 728–738. 3 indexed citations

Forlenza, Gregory P., Daniel J. DeSalvo, Grazia Aleppo, et al.. (2024). Real-World Evidence of Omnipod ^® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics. 26(8). 514–525. 36 indexed citations

DeSalvo, Daniel J., Bruce W. Bode, Gregory P. Forlenza, et al.. (2024). Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod ^® 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics. 26(6). 383–393. 12 indexed citations

Jendle, Johan, Peter Adolfsson, Pratik Choudhary, et al.. (2023). A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective. Diabetologia. 67(2). 236–245. 14 indexed citations

Ylescupidez, Alyssa, Cate Speake, Susan L. Pietropaolo, et al.. (2023). OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal of Clinical Endocrinology & Metabolism. 109(1). 57–67. 19 indexed citations

10.

Messer, Laurel H., Kellee M. Miller, Mark A. Clements, et al.. (2023). Adolescent- and Young Adult-Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial. Pediatric Diabetes. 2023. 1–10. 1 indexed citations

11.

Hood, Korey K., William H. Polonsky, Sarah A. MacLeish, et al.. (2023). Psychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers. Pediatric Diabetes. 2023. 1–12. 6 indexed citations

12.

Huang, Jingtong, Richard M. Bergenstal, Kristin Castorino, et al.. (2023). Update on Measuring Ketones. Journal of Diabetes Science and Technology. 18(3). 714–726. 22 indexed citations

13.

Buckingham, Bruce A., et al.. (2022). Pharmacodynamics, pharmacokinetics, safety, and tolerability of a ready‐to‐use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes. Pediatric Diabetes. 23(6). 754–762. 1 indexed citations

14.

Shang, Trisha, Jennifer Y. Zhang, B. Wayne Bequette, et al.. (2021). Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology. 15(4). 916–960. 2 indexed citations

15.

Sherr, Jennifer L., Bruce W. Bode, Gregory P. Forlenza, et al.. (2021). 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). Diabetes. 70(Supplement_1). 1 indexed citations

16.

Forlenza, Gregory P., Bruce A. Buckingham, Jennifer L. Sherr, et al.. (2020). 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes. 69(Supplement_1).

17.

Sherr, Jennifer L., Bruce A. Buckingham, Gregory P. Forlenza, et al.. (2020). 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia. Diabetes. 69(Supplement_1).

18.

Sherr, Jennifer L., Bruce A. Buckingham, Gregory P. Forlenza, et al.. (2019). Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics. 22(3). 174–184. 60 indexed citations

19.

Waldron-Lynch, Frank, et al.. (2014). Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomized controlled trial. eScholarship (California Digital Library). 16.

20.

Cengiz, Eda, Stuart A. Weinzimer, Jennifer L. Sherr, et al.. (2013). Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming. Diabetes Technology & Therapeutics. 16(1). 20–25. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact